• Funding for research and clinical trials related to long term studies of COVID-19 at the National Institutes of Health provided in the Consolidated Appropriations Act of 2021 (PL 116-260); Funding for Long-Covid studies in the FY 2023 appropriations. Potential funding for long COVID-related research (HR 4502, no Senate number yet).
• Issues associated with diagnosing and treating the effects of COVID-19 appropriately (HR 2754).; NASH Care Act (no bill number yet).
• Reimbursement of new technologies in Medicare, including the Medicare Coverage of Innovative Technology Program (No specific legislation) and ARPA-H legislation (DeGette/Upton, HR 5585)
• Food and Drug Administration regulation of medical devices, monitor development of Medical device user fee legislation

Duration: February 1, 2021 to June 30, 2022

General Issues: Budget/Appropriations, Health Issues, Medicare/Medicaid, Medical/Disease Research/Clinical Labs

Spending: about $230,000 (But it's complicated. Here's why.)

It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.

Agencies lobbied since 2021: U.S. Senate, House of Representatives, Natl Institutes of Health (NIH), Centers For Disease Control & Prevention (CDC), Health & Human Services - Dept of (HHS), Food & Drug Administration (FDA)

Related Foreign Entities: Perspectum (Oxford, OX 42LL, GBR); contribution to lobbying: $0; ownership 100%